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INTRODUCTION
ADHD, one of the most frequently diagnosed neurobehav-
ioral diseases, is characterized by developmentally inappro-
priate attention deficit, hyperactivity, impulsivity.1,2 The num-
ber of ADHD patient is estimated up to 5-10% among child-
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ren worldwide, and approximately 70% of them persists until 
adolescence.3 It causes learning and behavioral problems, 
peer difficulties, low self-esteem, risk of adult crime and sub-
stance abuse.4,5
Currently, the stimulant medications, such as methylphe-
nidate, are most used medications as first line treatment for 
ADHD children. Although, methylphenidate has established 
better efficacy over other behavioral and psychosocial treat-
ments showing 70% of positive treatment response,6 only half 
of those diagnosed as ADHD receive treatment, with fewer 
than one third accessing specialty services7 and considerable 
variation in stimulant medication use among children with 
ADHD has been documented through researches. Disparities 
in use have been observed on biological factors such as age, 
gender, race/ethnicity, and cultural factors like community 
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socioeconomic characteristics, including parent’s attitude, 
stigma, clinician’s own training background and clinical expe-
rience.8-10
Lack of knowledge, stigma, concerns about the increasing 
use of psychotropic medications, and cost considerations have 
been cited as explanations for low rates of treatment seeking, 
adherence, and positive outcome. Additionally, parental be-
liefs that medication is inappropriate for major emotional or 
behavioral problems in childhood, contribute to low treatment 
rates of psychostimulants, also.11 
In cross cultural aspect, the treatment rates for behavioral 
disorders have reported to be lower in non-Western children 
as compared to Western children.12 As regard of Asian cultural 
society, we suggest cultural background would affect dosing 
and titration of methylphenidate in treating ADHD children, 
thus determination of the optimal dose for ADHD children 
would be more delicate in Korea, like Asian countries. 
The Osmotic-controlled Release Oral delivery (OROS)-me-
thylphenidate of extended release tablet has been recently de-
veloped to eliminate the inconvenience of multiple dosing of 
immediate-release methylphenidate.13 Ever since the first re-
lease of OROS-MPH in Korea in 2003, OROS-MPH use has 
steadily increased to 53,425 of children with ADHD were pre-
scribed with OROS-MPH in 2006.14 However, cultural influ-
ences and media’s reports have a great impact on OROS-MPH 
use, clinically. In terms of that point, it is important to explore 
moderating factors associated with titration and dosing of 
methylphenidate in a Korean population. 
The hypothesis of this study was that the optimal dosage of 
OROS-MPH would be determined by age, subtypes of ADHD, 
symptom severity and severity of adverse effects.
The aim of this study was to examine the pattern of dose ti-
tration and optimal dose of OROS-MPH, and to evaluate the 
relationship between the optimal dose and associated clinical 
issues including tolerability, ADHD subtype and symptom 
severity in Korean subjects with ADHD. 
METHODS 
Subjects
We conducted our trial on 143 children, aged from 6 to 18- 
year-old who were diagnosed as ADHD, based on clinical ev-
aluation using Diagnostic and Statistical Manual of Mental 
disorder, Fourth Edition (DSM-IV) criteria, confirmed by st-
ructured interview (using the Kiddie Schedule for Affective 
Disorders and Schizophrenia)15 All subjects were not exposed 
to OROS-MPH within 3 months. 
Exclusion criteria
The children, suffered from the following disease, were not 
included in this procedure; mental retardation (IQ under 70), 
Tourette syndrome, chronic tic disorders, psychotic disorders, 
seizure disorders, brain injury, pervasive developmental disor-
ders, severe medical or surgical disorders and planning to start 
or change behavioral therapy as well as those children who 
were taking selective serotonin reuptake inhibitor and antipsy-
chotics within 4 weeks.
Procedures
Each subject’s parents were required to give signed inform-
ed consent. Written approval of the study design was obtained 
from the institutional review board for all participating centers 
before initiation of the study. This multisite study (7 sites) con-
sisted of 24-hour washout period and 12-week open-labeled 
dose titration period. After a 24-hour washout period during 
which all previous drugs for ADHD were discontinued, sub-
jects underwent a series of baseline assessments; Korean-We-
chsler Intelligence Scale for Children (K-WISC-II), vital signs, 
medical history, physical examination, laboratory test, electro-
cardiography. Subjects then entered the open-label dose ti-
tration phase. An individualized dosage of OROS-MPH was 
determined for each subject based on clinical evaluation per-
formed by child psychiatrists in each site. The criteria of re-
sponse, defined as Korean ADHD Rating Scale (K-ARS) <1816 
and Clinical Global Impression-Improvement (CGI-I) 6 or 7.17 
If the psychiatrist judge the criteria of response was not met 
for the child, the subject received increased dose of OROS-
MPH, 18 mg/d or 27 mg/d. Subjects were evaluated on week 
1, week 3, week 6, week 9 and week 12. CGI-I, Side-effects rat-
ing scale (SRS), Adverse events, K-ARS were assessed at every 
visits.
Study measures
Korean ADHD Rating Scale
The Korean ADHD Rating Scale consists of 18 items that as-
sess DSM-IV criteria for inattention and hyperactivity. Items 
are scored on a 4-point scale (from 0, never or rarely, to 3, very 
often). The Korean version was found to demonstrate dis-
criminant validity18 and has been used in treatment studies.19 
ADHD is suspected if total score is above 19. 
Clinical Global Impression-improvement
The investigator-rated global assessment of effectiveness 
uses a 7-point scale (from 7, very much worse, to 1, very much 
improved) to evaluate the response of the subject to the cur-
rent treatment. 
Side-effects Rating Scale
Side-effects Rating Scale, developed by Barkley,20 consists of 
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17 most commonly reported adverse effects of methylpheni-
date. Each item is rated on a 10-point scale (0: none through 
the past week, to 9: very severe).
Statistical analysis 
Demographic characteristics were summarized in descrip-
tive statistics. Repeated measures analyses of variance or mul-
tivariate analyses of variance were used to evaluate treatment 
effectiveness for ADHD subtype. Pearson correlation was 
performed to examine the relationship between dose and SRS, 
K-ARS scores. Statistical significance was indicated by p-val-
ues of 0.05 or less. All statistics were demonstrated under 
SPSS 12.0.
RESULTS 
Diagnostic and descriptive information 
A total of 143 children were participated in the study from 
March 1, 2006 to September 31, 2006, at different 6 centers 
in South Korea. Twenty-seven of children could not complete 
the procedure of treatment for the following reasons: non-
compliance of medication (12 subjects, 44.4%), adverse effects 
(8 subjects, 29.6%), follow up loss (6 subjects, 22.2%) and oth-
ers (1 subject, 3.7%). 
The demographic and baseline characteristics of subjects 
are given in Table 1. The average age of the participants was 
9.36±2.4 years and most of participants were male. 128 par-
ticipants were drug naïve, 10 of them had received MPH tr-
eatment (Immediate Release MPH) and others were taking 
non MPH medications such as desmopressin, topiramate, pra-
zocin, hydroxyzine, clenbutenol. 
Dosing pattern
Of the 116 subjects who successfully completed the study, 
77 (66.4%) subjects achieved the criteria for response (K-ARS 
<18 and CGI-I 6 or 7). The average total daily dose for sub-
jects who responded was 30.05±12.52 mg per day (0.90±0.31 
mg/kg/d). The optimal dosage for the subjects in this study 
was regarded as the dosage which was effective (according to 
above response criteria) and tolerable (no and minimal ad-
verse effects) in every single child. The titrating procedure was 
performed flexible and naturalistic depending on individual 
response and tolerability. Their individualized dosage of 
OROS methylphenidate were 25 subjects (32.5%) at 18 mg, 
25 subjects (32.5%) at 27 mg, 13 subjects (16.9%) at 36 mg, 8 
subjects (10.4%) at 45 mg, 4 subjects (5.2%) at 54 mg, and 2 
subjects (2.6%) at 72 mg. The average daily dose increased 
from 19.20±3.11 mg per day (0.64±0.18 mg/kg/d) at week 1 
to 34.13±13.80 mg per day (1.03±0.3318 mg/kg/d) at the end 
of 12 weeks of dosing (Figure 1).
Different treatment response in ADHD subtype
Of the 116 children who completed the study, twenty seven 
(33.6%) subjects received a diagnosis of ADHD inattentive-
predominant type, twenty eight (36.2%) subjects were com-
bined type, three (5.2%) were hyperactive-impulsive type and 
nineteen(25.5%) subjects were not otherwise specified type. 
There was no difference in mean daily dose and weight/dose 
between subtypes on ANOVA. 
Safety and tolerability 
The majority of adverse events reported during the study 
were judged to be mild. Of the 143 children treated in the stu-
dy, 121 children (84.6%) reported at least one adverse event. 
Adverse events that were suspected to be treatment-related 
and occurred in ≥1% of subjects at any time during the 12-
week period are presented in Table 2. Eight subjects discon-
tinued study medication prematurely because of adverse ev-
Table 1. Demographics and baseline clinical characteristics (N= 
143)
Characteristics Subjects, N (%)
Age (years)
0-9 74 (0.8)
9-12 46 (0.8)
12< 23 (1.2)
Mean (SD) 9.36 (2.4)
Sex
Male 121 (84.6)
Female 22 (15.1)
ADHD subtype
Inattentive predominant 49 (34.3)
Hyperactive-impulsive 9 (6.3)
Combined 50 (35.4)
Not otherwise specified 35 (24.5)
Comorbidity
Tic disorder 12 (7.0)
Any anxiety disorder 7 (3.9)
Depression 6 (4.1)
ODD/Conduct disorder 39 (27.3)
Previous pharmacotherapy
None 128 (89.5)
Non-MPH 5 (3.5)
IR-MPH 10 (6.9)
Weight (kg) 36.9 (14.9)
Height (cm) 137.3 (15.1)
IQ Mean (SD) 108.13 (15.3)
ADHD: attention-deficit/hyperactivity disorder, ODD: opposition-
al defiant disorder, MPH: methylphenidate, IQ: intelligence quotient
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ents. These events included loss of appetite, anorexia, tic, sei-
zure, abdominal pain and headache. There was a significant 
difference in mean changes for systolic, diastolic blood pres-
sure and heart rate between baseline and the end of the open-
label phase. Systolic BP increased from 105.29±12.65 mm Hg 
to 108.39±70.92 mm Hg (p=0.001), diastolic BP from 66.85± 
10.12 mm Hg to 70.92±10.47 mm Hg (p=0.001) and heart 
rate from 82.68±14.63/min to 89.06±14.83/min (p=0.001). 
No significant changes were observed on EKG. Mean absolute 
weight decreased over the course of the study (baseline 36.91± 
14.97 kg vs. endpoint 35.67±14.18 kg). 
To examine side effects of OROS-MPH dose, we compar-
ed weekly SRS scores. Total SRS scores decreased though out 
the course. OROS-MPH dose did not have a significant effect 
on SRS total score (F=2.18, p=0.074), however, in specific 
items of SRS, only insomnia and abdominal pain remained wi-
thout a significant decrease (t=-0.690, t=2.154). The results 
show that adverse effects are less likely to be reported as tr-
eatment proceeds, unrelated to the dose of OROS-MPH. 
Adverse effects and optimal dose
On Pearson’s product moment correlation coefficient, there 
was no significant relationship between dose and SRS scores 
at baseline and endpoint in whole subjects (n=143). The same 
result was observed in dose/weight and SRS scores of baseline 
and endpoint, also. Therefore, no correlation was found be-
tween the optimal dose and severity of adverse effects (Table 3). 
Different optimal dosage by age in responded group
The subjects who responded to OROS-MPH were divided 
into 3 groups by age; below 9, between 9 and 12, and above 12. 
On ANOVA mean dose and mean weight dose showed sta-
tistically different between 3 groups. Comparing the differ-
ences between the groups by post hoc test, the mean dose of 
age below 9 was lower than age above 12, age between 9 and 
12 was also younger than age above 12, and age below 9 was 
lower than between 9 and 12. The mean dose/weight of age 
below 9 was significantly higher than those of age between 9 
and 12, and above 12 (F=5.584, p<0.01)(Table 4). 
Correlation between ADHD symptom severity and 
OROS-MPH dose 
There were some significant relationships reported between 
variables using Pearson’s product moment correlation coeffi-
cient in total subjects (n=143)(Table 5). There was a highly 
significant and positive correlation between dose and base-
line K-ARS scores (r=0.275, p=0.001) and also a positive cor-
relation between dose and endpoint K-ARS scores (r=0.365, 
p=0.001). Dose/weight was found to have a significant posi-
tive correlation with only baseline K-ARS scores (r=0.233, 
p=0.041). We found that dose and dose/weight increased de-
pending on ADHD symptom severity. 
Mean total 19.20 27.23 31.44 33.50 34.13
  daily dose (mg)
Mean  0.64 0.82 0.93 0.95 1.03
  weight (mg/kg)
Figure 1. Average daily dose of OROS methylphenidate by week. 
OROS: Osmotic-controlled Release Oral delivery.
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Table 2. Adverse events related to study medication reported by 
≥1% of the total participants (N=143)
Event   Subjects, N (%)
Anorexia 104 (30.95)
Insomnia 44 (13.10)
headache 30 (8.93)
Abdominal pain 20 (5.95)
Dizziness 15 (4.46)
Anxiety 12 (3.57)
Nightmare 10 (2.97)
Stomach ache 9 (2.68)
Irritability 9 (2.68)
Nervousness 9 (2.68)
Nausea 9 (2.68)
Tics 7 (2.08)
Somnolence 6 (1.79)
Depression 5 (1.49)
Weight loss 4 (1.19)
Table 3. Correlation between optimal dose and SRS in the sub-
jects who responded to OROS-MPH (N=77)
Dose Dose/Weight Baseline SRS
Dose/Weight  (r) 0.357**
Baseline SRS (r) 0.057 0.207
Endpoint SRS (r) -0.203 -0.019 0.446**
By Pearson correlation analysis. *correlation significant at the 0.05 le-
vel, **correlation significant at the 0.001 level. OROS-MPH: Osmotic-
controlled Release Oral delivery methylphenidate, SRS: Side-effects 
Rating Scale, r:  Pearson correlation coefficient (ranged from -1.0 to 1.0)
DH Song et al. 
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DISCUSSION 
This study was the first open labeled trial conducted for 12 
weeks in 6 credible medical centers of Korea. The results sh-
owed differences in the optimal dose by age and symptom se-
verity, and there were no differences by severity of adverse ef-
fects and subtypes of ADHD. 
The overall mean daily dose of OROS-MPH which shows 
a clinical response was 30.05±12.52 mg/d, 0.90±0.31 mg/kg/d. 
In comparison with other Korean optimal studies, this result 
was higher than others. The reported dose was 0.87 mg/kg/d 
after 3 weeks of OROS-MPH treatment without previous me-
dication history, and dose increased with weight and age.21 In 
another trial,22 the optimal dose was 0.74 mg/kg/d after 3- 
week treatment of drug naïve children. This trial was proceed-
ed for 12 weeks, relatively longer period of time than previous 
Korean studies.21-23 The increase of optimal dose during titra-
tion phase is in line with 12 month follow up study that re-
ported increased dose after 12 months of treatment and the 
amount of increase is greater in the first 3 months.24
The differences in optimal dosage on different ages were 
observed. The younger the age, much dose/weight was need-
ed to control ADHD symptoms. Present findings are consis-
tent with previous studies, which were thought to be influ-
ences of different pharmacokinetics by age.25-27
In contrast to previous studies that reported inattentive-pre-
dominant type was more effective with lower dose, while com-
bined type, with greater dose,28,29 differences of optimal dosage 
by ADHD subtypes were not observed. This may reflect limi-
tations on classification of subtypes based on rating scale or 
interviews, not on direct observation or attention test, and too 
small number of samples in each subtype. 
Most common adverse effects were anorexia (30.95%), in-
somnia (13.10%), headache (8.93%), in similar with other stu-
dies,26,30 none reported any severe or life-threatening effects of 
methylphenidate. Differences in adverse effects by dose were 
not observed, this is evident in previous trials.21,27,29
In interpreting the results, several limitations should be kept 
in mind. First, methodologically, since this was an open-label 
trial without placebo, the results were subject to observer bias. 
Also, evaluation was limited in safety and tolerability for the 
same reason. Second, a positive bias may have resulted from 
enrollment of only subjects who could tolerate OROS-MPH 
and experienced efficacy during the dose titration phase. Third, 
our sample may not reflect and generalize to unselected chil-
dren in clinical practice. Children with unstable psychiatric 
and medical disorder were excluded from the sample. Fourth, 
titration phase was limited to a 12-week trial, which was the 
longest trial of the studies performed in Korea, however, our 
findings may not be generalized to long term effects of meth-
lyphenidate. 
Nevertheless, this open labeled trial is the first study to de-
termine optimal dosage of OROS-MPH to establish its effica-
cy and safety in Korean children with ADHD. In the future, 
we will need to perform a multisite randomized controlled 
study for evaluating the long-term effect and tolerability of 
OROS-MPH in Korean subjects with ADHD. 
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